ArticlePloS one2016
Hepatotoxicity during Treatment for Tuberculosis in People Living with HIV/AIDS.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Malnutrition assessment methods in adult patients with tuberculosis: a systematic review.BMJ open · 2021Pooled it
- Trial
- Incidence, risk factors, and outcomes of anti-tuberculosis drug-induced hepatotoxicity in people with and without HIV in Thailand and the Philippines.Asian biomedicine : research, reviews and news · 2026Article
- Incidence and risk factors of abnormal liver function and anti-tuberculosis drug-induced liver injury: a multicenter retrospective study involving 482 chinese pediatric tuberculosis patients.Annals of medicine · 2025Article
- Pharmacogenetics of tuberculosis treatment toxicity and effectiveness in a large Brazilian cohort.Pharmacogenetics and genomics · 2025Observational
- Antimicrobial and Antiproliferative Properties of 2-Phenyl-N-(Pyridin-2-yl)acetamides.Chemical biology & drug design · 2025Article
- Risk factors associated with post-tuberculosis sequelae: a systematic review and meta-analysis.EClinicalMedicine · 2024Article
- Clinical standards for the management of adverse effects during treatment for TB.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2023Article
- Hybrid use of Raman spectroscopy and artificial neural networks to discriminate Mycobacterium bovis BCG and other Mycobacteriales.PloS one · 2023Article
- HIV Infection Predisposes to Increased Chances of HBV Infection: Current Understanding of the Mechanisms Favoring HBV Infection at Each Clinical Stage of HIV Infection.Frontiers in immunology · 2022Review
- Inclusion Complexes of Rifampicin with Native and Derivatized Cyclodextrins:Pharmaceuticals (Basel, Switzerland) · 2021Article
- Tuberculosis diagnostics: overcoming ancient challenges with modern solutions.Emerging topics in life sciences · 2020Review
- Tuberculosis in HIV-Associated Cryptococcal Meningitis is Associated with an Increased Risk of Death.Journal of clinical medicine · 2020Article
- Abnormal Levels of Liver Enzymes and Hepatotoxicity in HIV-Positive, TB, and HIV/TB-Coinfected Patients on Treatment in Fako Division, Southwest Region of Cameroon.BioMed research international · 2020Article
- The clinical impact of drug-induced hepatotoxicity on anti-tuberculosis therapy: a case control study.Respiratory research · 2019Article
- Mannose-binding lectin concentrations in people living with HIV/AIDS infected by HHV-8.BMC immunology · 2019Article
- Rifamycin action on RNA polymerase in antibiotic-tolerantProceedings of the National Academy of Sciences of the United States of America · 2017Article
- Genome-Wide Association and Replication Study of Hepatotoxicity Induced by Antiretrovirals Alone or with Concomitant Anti-Tuberculosis Drugs.Omics : a journal of integrative biology · 2017Article
- Pyrazinamide clearance is impaired among HIV/tuberculosis patients with high levels of systemic immune activation.PloS one · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatotoxicity is frequently reported as an adverse reaction during the treatment of tuberculosis. The aim of this study was to determine the incidence of hepatotoxicity and to identify predictive factors for developing hepatotoxicity after people living with HIV/AIDS (PLWHA) start treatment for tuberculosis. This was a prospective cohort study with PLWHA who were monitored during the first 60 days of tuberculosis treatment in Pernambuco, Brazil. Hepatotoxicity was considered increased levels of aminotransferase, namely those that rose to three times higher than the level before initiating tuberculosis treatment, these levels being associated with symptoms of hepatitis. We conducted a multivariate logistic regression analysis and the magnitude of the associations was expressed by the odds ratio with a confidence interval of 95%. Hepatotoxicity was observed in 53 (30.6%) of the 173 patients who started tuberculosis treatment. The final multivariate logistic regression model demonstrated that the use of fluconazole, malnutrition and the subject being classified as a phenotypically slow acetylator increased the risk of hepatotoxicity significantly. The incidence of hepatotoxicity during treatment for tuberculosis in PLWHA was high. Those classified as phenotypically slow acetylators and as malnourished should be targeted for specific care to reduce the risk of hepatotoxicity during treatment for tuberculosis. The use of fluconazole should be avoided during tuberculosis treatment in PLWHA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.